• Resurrect Bio

  Participated · Series A · May 2026

  Resurrect Bio’s core product is its FloraFold AI platform, trained to predict protein–protein interactions between crops and pathogens, coupled with high-throughput in-silico and in-planta screening to validate candidates. The company identifies pathogen effectors that bind plant NLR immune proteins and recommends specific, often minimal, gene edits for partners to break those interactions and restore resistance. Resurrect Bio does not perform the gene edits itself but provides precise targets and instructions to seed companies and breeders. It has demonstrated proof points such as conferring resistance to potato cyst nematode and has a joint development agreement with Corteva to work on corn disease resistance. Founded in December 2021 as a spinout from The Sainsbury Laboratory in Norwich, the company has raised a total of $12.4M and will use the new capital to grow its team and advance development of disease-resistance traits.

• HotHouse Therapeutics

  Participated · Seed · Dec 2025

  HotHouse Therapeutics, based in Norwich, Norfolk, has developed an AI-driven plant bioengineering system capable of designing and growing new chemistry within days. The platform combines pathway-prediction algorithms with the vast enzymatic diversity of the plant kingdom and can currently generate over 20 million novel molecules. Its vertical-farm-ready production process is carbon positive, offering a sustainable and affordable alternative to extractive or resource-heavy chemical synthesis. The company’s initial commercial focus is on producing next-generation vaccine adjuvants, but management also plans to launch traditional drug-discovery programs and progress selected assets into clinical development. By coupling rapid molecule generation with scalable cultivation, the company aims to shorten R&D timelines and lower production costs for biologically active compounds. The recent funding marks the company’s first institutional capital, positioning it to expand operations and intensify R&D efforts around its discovery pipeline.

• Scindo

  Participated · Equity · Sep 2025

  Founded in 2020, Scindo has built a proprietary, data-rich platform that combines experimentally validated reaction datasets with advanced AI models to discover, design and optimise novel enzymes. These enzymes catalyse the conversion of challenging, renewable feedstocks directly into bio-active ingredients, offering a sustainable alternative to petroleum-derived chemicals. The company positions its technology as a full-stack solution that enables consistent, scalable production of natural ingredients across multiple high-value sectors such as food, flavourings, cosmetics and specialty chemicals. Industry traction is already evident through partnerships with leading specialty chemical manufacturers and pilot-scale initiatives aimed at bringing the first products to market. Recent hiring from top pharmaceutical firms and the University of Oxford has strengthened expertise in machine learning, enzyme engineering, process scaling and commercialisation. Proceeds from the latest funding will expand the enzyme discovery engine, scale wet-lab capabilities and grow the team. The company did not disclose revenue or user metrics, but investor interest highlights strong demand for bio-based solutions that deliver both performance and sustainability.

• Solena Materials

  Participated · Seed · May 2025

  Solena Materials develops computationally designed proteins intended for use as textile fibres, leveraging an AI-driven protein design platform. The company, founded in 2022 as a spinout from Imperial College London, is working with The Protein Express on the EXPREST program to advance manufacturability at scale. Under EXPREST, Solena will focus on designing a high-performance spinnable protein while the partner advances industrial fermentation and scalable purification processes. The program includes generating LCA and TEA data and pursuing EU REACH regulatory alignment to support commercial readiness. Solena and its partner are initially targeting the performance and premium apparel markets, with potential applicability across the broader textile industry. The company’s current financing includes the €1.4 million awarded through the Eureka Eurostars programme for the EXPREST collaboration.

• Generare

  Participated · Seed · Oct 2024

  Generare builds a platform combining high-throughput cloning and sequencing to identify, express, and characterise novel small molecules from microbial genomes, generating structured data on their properties. The company is focused on expanding the accessible chemical space for drug discovery by creating a large-scale dataset of previously unexplored molecular diversity. Founded in 2023, Generare reports growing adoption of its platform among pharmaceutical and research organisations, with discovered molecules entering early-stage drug development. Its immediate plans include expanding its compound library, scaling its discovery capabilities, and hiring across a multidisciplinary team to meet demand. Financially, the company recently secured €20 million in a Series A to fund those growth initiatives.

No current team members are available.